Neuroendocrine Tumor Recurrence: Diagnosis with68Ga-DOTATATE PET/CT
نویسندگان
چکیده
منابع مشابه
Pitfalls in neuroendocrine tumor diagnosis
Carcinoids, originating from cells of the diffuse endocrine system (DES), account for 0.7% of all malignancies and are characterized by a slow growth rate and the presence of nonspecific signs and symptoms often making their detection rather difficult. Gastroente ropancreatic neuroendocrine tumors (GEP-NETs) represent the majority (~70%) of DES tumors. Historically they account for about 2% of ...
متن کاملIntra-pancreatic Accessory Spleen Mimicking Pancreatic Neuroendocrine Tumor on 68-Ga-Dotatate PET/CT.
Neuroendocrine tumors (NETs) are rare tumors, but the incidence is increasing with new diagnostics. A 37-year-old man was admitted to our hospital for an incidental 17-mm nodule in the tail of the pancreas. PET/CT shows indeterminate mass in the pancreatic tail with enhanced uptake of 68-Ga-dotatate. NET was suspected and laparoscopic distal pancreatectomy was performed. Pathologic examination ...
متن کاملBiochemical diagnosis of neuroendocrine GEP tumor.
Neuroendocrine gut and pancreatic tumors are known to contain and secret different peptide hormones and amines. During the last two decades, many radioimmunoassays and Elizas have been developed to analyze these substances in blood and urine, which has enabled clinicians to improve the diagnosis and monitoring of patients with various neuroendocrine tumors. Due to cost constraints in medical ca...
متن کاملGa-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience
Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, majority of which express somatostatin (SST) receptors. Recently, with the widespread use of positron emission tomography/computed tomography (PET/CT) and development of novel PET tracers like Ga-68 DOTA peptide which specifically bind to somatostatin receptors (SSTR), Ga-68 DOTA peptide PET/CT is used in manageme...
متن کاملEfficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
BACKGROUND The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, (90)Y labelled Tyr3-octreotate, ((90)Y-DOTATATE) in neuroendocrine tumours (NETs). MATERIAL AND METHODS 46 patients with disseminated or non-operable NET were enrolled in this study. The (90)Y-DOTAT...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiology
سال: 2013
ISSN: 0033-8419,1527-1315
DOI: 10.1148/radiology.13122501